FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV(max) as a predictive biomarker in frontline treatment of mantle cell lymphoma

采用定性 Lugano 标准进行 FDG-PET/CT 疗效评估,在套细胞淋巴瘤一线治疗中,其作为预测性生物标志物的性能优于 SUV(max) 变化。

阅读:2

Abstract

(18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is routinely used for initial staging and response assessment for the majority of lymphoma subtypes. Several techniques for FDG-PET/CT response assessment have been studied, with the Lugano criteria utilizing the Deauville five-point scale (5-PS) becoming widely adopted as a favored approach. More recently, novel static and dynamic FDG-PET/CT parameters have been explored, including baseline maximum standardized uptake value (SUV(max)) as well as change in SUV(max) (ΔSUV(max)) at either interim or end-of-treatment (EOT) response assessments, with a focus on diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma. We performed a broad assessment of multiple FDG-PET/CT parameters in a diverse cohort of patients with newly diagnosed mantle cell lymphoma (MCL). In contrast to other subtypes of lymphoma, we surprisingly found that higher baseline SUV(max) was not associated with other well-established adverse risk factors in MCL and was not prognostic for patient outcomes. We explored ΔSUV(max) at interim and EOT assessments, observing remarkably weak relationships between these parameters and patient outcomes, which also contrasted with the strong relationships between these parameters and patient outcomes in DLBCL. Instead, standard response assessment via the Lugano criteria utilizing the Deauville 5-PS score had the most robust prognostic value of the FDG-PET/CT parameters assessed in our study. Overall, we provide evidence for applying caution when extrapolating the prognostic value of FDG-PET/CT-based parameters across lymphoma subtypes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。